Compare ASPI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPI | CMPX |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.3M | 408.8M |
| IPO Year | 2022 | 2020 |
| Metric | ASPI | CMPX |
|---|---|---|
| Price | $4.28 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $12.00 | ★ $14.57 |
| AVG Volume (30 Days) | ★ 3.9M | 3.1M |
| Earning Date | 04-10-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $23,849,000.00 | N/A |
| Revenue This Year | $68.41 | N/A |
| Revenue Next Year | $126.69 | $934.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $3.51 | $1.61 |
| 52 Week High | $14.49 | $6.88 |
| Indicator | ASPI | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 59.56 |
| Support Level | $3.98 | $1.82 |
| Resistance Level | $5.88 | $2.47 |
| Average True Range (ATR) | 0.28 | 0.13 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 85.79 | 80.37 |
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.